Volume 90, issue 11, Novembre 2003

DOSSIER THÉMATIQUE

Costs, costs and more costs: which one should we use? (p.946-54)
Robert Launois, Alain Vergnenègre, Bernard Garrigues

The cost of imaging in oncology practice (p.961-8)
Sophie Taïeb

The cost of radiotherapy (p.969-75)
P. Martin

The cost of chemotherapy (p.976-82)
Christine Lévy, Julia Bonastre

The cost of screening for breast and cervical cancer in France (p.997-1004)
Suzanne Wait

The cost of cancer in France: macroeconomic and microeconomic approaches, evolution towards a prospective payment system (p.1005-9)
Lionel Perrier, Laurent Borella, Thierry Philip

Assessment of cancer cost at the international level : challenges and methodological approaches (p.1016-23)
Ralph Crott

Medicine, ethics and money (p.1024-6)
Bernard Hœrni, Antoine Avril

Dossier thématique

Methodology of economic assessment: example in oncology (p.939-45)
Isabelle JAISSON‐HOT, Anne‐Marie SCHOTT, Christine CLIPPE, Christell GANNE, Touria HAJRI, Bénédicte PONCET, Véronique TRILLET‐LENOIR, Cyrille COLIN

Which medico‐economic approaches must be taken to evaluate the impact of costly molecules in oncology? The model of Herceptin ^® in the breast metastatic cancer (p.955-60)
Christell Ganne, Véronique Trillet‐Lenoir, Isabelle Jaisson‐Hot, Franck Chauvin, Christine Clippe, Marie‐Odile Heilmann, Touria Hajri, Bénédicte Poncet, Catherine Heuclin, Cyrille Colin

Economic assessment of Caelyx ^® versus topotecan in advanced ovarian cancer (p.983-8)
Véronique Girre, Éric Pujade‐Lauraine, Isabelle Durand‐Zaleski

Refining the French system of cost assessment for oncology patients following chemotherapy (p.989-96)
Christine Lévy‐Piedbois, Laurent Borella, Philippe Bergerot, Patrick Peuvrel, Cristel Erard, Gérard Parmentier, Alain Ravaud, Béatrice Trombert Paviot, Jean‐Pierre Armand, Jean‐Marie Rodrigues

The "Plan Cancer" in France: an economists‘ point of view (p.1010-5)
Jean‐Paul Moatti, Anne‐Gaëlle Le Corroller, Soriano Christel Protière

Hommage

Ferdinand Cabanne (1920‐2003) (p.933-4)
Pierre Dussère, Robert Michiels, Jean‐Claude Horiot

Brèves

Un mécanisme d‘action original pour TIMP2, un inhibiteur tissulaire de métalloprotéases de la matrice. (p.935)
Gilles L‘Allemain
Open Access

Hsp90 : comment un chaperon devient une cible pharmacologique (p.935)
Alain Jacquemin‐Sablon
Open Access

ÉDITORIAL

Le coût du cancer, pour qui ? pour quoi ? (p.937)
Paul Cappelaere